- Secures approval for 'Hunterase IV' in India and both 'Hunterase IV & ICV' in Taiwan, accelerating expansion into the Asian rare disease market YONGIN, South Korea, Aug. 24, 2026 /PRNewswire/ -- GC Biopharma (006280.KS), a leading global pharmaceutical company based in South Korea,...
Hence then, the article about gc biopharma s hunter syndrome treatment hunterase receives drug approval in india and taiwan was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( GC Biopharma's Hunter Syndrome Treatment 'Hunterase' Receives Drug Approval in India and Taiwan )
Also on site :
- Mary Janes Are ‘Timeless’ Fall Footwear, and This ‘Chic’ $30 Pair Is ‘Comfortable’ All Day With No Break-in Required
- Ukraine hands Britain ‘goldmine’ of secret battlefield intelligence to protect bases from Russian spies
- Professional Chef Says These 3 ‘Old-Fashioned’ Meals from the 1940s Are the Definition of ‘Comfort Food’